A phase II, randomized, observer-blinded, controlled, parallel group clinical trial with decentralized elements to evaluate the safety and efficacy of PB-TX-01 in patients with chronic wounds colonized by Pseudomonas aeruginosa
Latest Information Update: 31 Mar 2026
At a glance
- Drugs PB TX 01 (Primary)
- Indications Bacterial infections
- Focus Adverse reactions
- Sponsors PathoBlock Therapeutics
Most Recent Events
- 31 Mar 2026 New trial record